Nikos Stratakis, David V. Conti, Ran Jin, Katerina Margetaki, Damaskini Valvi, Alexandros P. Siskos, Léa Maitre, Erika Garcia, Nerea Varo, Yinqi Zhao, Theano Roumeliotaki, Marina Vafeiadi, Jose Urquiza, Silvia Fernández‐Barrés, Barbara Heude, Xavier Basagana, Maribel Casas, Serena Fossati, Regina Gražulevičienė, Sandra Andrušaitytė, Karan Uppal, Rosemary R.C. McEachan, Eleni Papadopoulou, Oliver Robinson, Line Småstuen Haug, John Wright, Miriam B. Vos, Hector C. Keun, Martine Vrijheid, Kiros T. Berhane, Rob McConnell, Lida Chatzi – 1 August 2020

Nilesh Sadashiv Patil, Viniyendra Pamecha, Piyush Kumar Sinha, Dharmendra S. Dangi, Nihar Mohapatra – 31 July 2020

31 July 2020

Shaleen Agarwal, Rajesh Dey, Yuktansh Pandey, Sapana Verma, Subash Gupta – 31 July 2020 – Recipient hepatic artery intimal dissection (HAD) followed by hepatic artery thrombosis (HAT) is a serious complication of liver transplantation. Once this is recognized intraoperatively, the accepted approach is to use an alternative arterial inflow, which may not be possible in all patients. We describe a new classification and technique for the management of HAD during living donor liver transplantation. On the basis of the longitudinal extent of intimal dissection, HAD was classified into 4 types.

Deniz Balci, Elvan Onur Kirimker, Meltem Bingol Kologlu, Evren Ustuner, Ufuk Utku Goktug, Suheyla Karadag Erkoc, Ali Abbas Yilmaz, Mustafa Kemal Bayar, Alpay Azap, Ramazan Erdem Er, Abdulkadir Dokmeci, Kaan Karayalcin – 31 July 2020

Melanie A. Hundt, Yanhong Deng, Maria M. Ciarleglio, Michael H. Nathanson, Joseph K. Lim – 29 July 2020

Allison J. Kwong, Avegail Flores, Giovanna Saracino, Jodi Boutté, Greg McKenna, Giuliano Testa, Ranjeeta Bahirwani, Anji Wall, W. Ray Kim, Göran Klintmalm, James F. Trotter, Sumeet K. Asrani – 29 July 2020 – In the United States, centers performing liver transplant (LT) are primarily evaluated by patient survival within 1 year after LT, but tight clustering of outcomes allows only a narrow window for evaluation of center variation for quality improvement. Alternate measures more relevant to patients and the transplant community are needed.

Anja Christina Koop, Nina Doreen Thiele, David Steins, Erik Michaëlsson, Malte Wehmeyer, Ludger Scheja, Babett Steglich, Samuel Huber, Julian Schulze zur Wiesch, Ansgar W. Lohse, Jörg Heeren, Johannes Kluwe – 29 July 2020 – Myeloperoxidase (MPO) activity has been associated with the metabolic syndrome, cardiovascular and liver disease. Here, we evaluate the therapeutic potential of MPO inhibition on nonalcoholic steatohepatitis (NASH) and NASH‐induced fibrosis, the main determinant of outcomes.

Andrea D. Branch – 28 July 2020 – Coronavirus disease 2019 (COVID‐19) has created an emergency of epic proportions. While a vaccine may be forthcoming, this is not guaranteed, as discussed herein.

Nikolaos Perakakis, Aditya Joshi, Natia Peradze, Konstantinos Stefanakis, Georgia Li, Michael Feigh, Sanne Skovgard Veidal, Glenn Rosen, Michael Fleming, Christos S. Mantzoros – 28 July 2020 – CHS‐131 is a selective peroxisome proliferator‐activated receptor gamma modulator with antidiabetic effects and less fluid retention and weight gain compared to thiazolidinediones in phase II clinical trials. We investigated the effects of CHS‐131 on metabolic parameters and liver histopathology in a diet‐induced obese (DIO) and biopsy‐confirmed mouse model of nonalcoholic steatohepatitis (NASH).